XtalPi Inc.
Edit

XtalPi Inc.

http://www.xtalpi.com/
Last activity: 17.09.2026
Active
Categories: AIBiotechPharmaR&DSimulation
We are a quantum physics-based, AI-powered drug R&D company with the mission to revolutionize drug discovery and development by improving the speed, scale, novelty and success rate. With operations in both China and the U.S., we strive to deploy the best capabilities and resources available to us in each market to meet the needs of our customers and collaborators.

Beyond our team’s domain expertise and creative thinking, the key to our mission is the integrated technology platform, which combines the mutually informing and reinforcing cloud supercomputing-powered in silico tools and our wet lab with robotic automation, and enables discovery and development of innovative therapeutics at a pace and scale beyond traditional alternatives. We are among the pioneering AI-powered drug R&D companies in the world that have established a platform with an iterative feedback loop between quantum physics-based dry lab and wet lab capabilities, according to Frost & Sullivan.

With our platform designed to improve dry lab calculations with experimental data generated by the wet lab and enhance the efficiency of the wet lab by insights derived from dry lab calculations, we believe that we are well positioned at this moment where the combination of AI, computing power, data and automation is becoming increasingly critical for pharmaceutical development.

Since our founding, we have received investments and support from world-renowned investors, and we believe this blue-chip shareholder base is a testament to our capabilities and prospects.
Followers
412
Website visits
21.4K /mo.
Mentions
83
Location: China
Employees: 201-500
Total raised: $380M
Founded date: 2014

Investors 3

Funding Rounds 3

DateSeriesAmountInvestors
29.09.2020Series C$319M-
29.10.2018Series B$46M-
23.01.2018Series B$15M-

Mentions in press and media 83

DateTitleDescription
17.09.2026Apex Intelligence Raises Nearly US$50 Million in Angel Funding to Build Self-Evolving Foundation Models-A Chinese Startup Enters the Global RSI Race. BEIJING, Sept. 16, 2026 /PRNewswire/ -- Apex Intelligence has completed its angel and angel-plus funding rounds, raising nearly US$50 Million in total. The angel round was co-led by IDG Capital...
26.08.2026ReviR Therapeutics Receives FDA Rare Pediatric Disease Designation for RTX-117 in Charcot-Marie-Tooth DiseaseDesignation supports the global development of RTX-117 and may provide potential future access to a transferable Priority Review Voucher, subject to approval and applicable requirements BRISBANE, Calif., Aug. 26, 2026 /PRNewswire/ -- ReviR ...
24.08.2026Overcoming the Limitations in siRNA Drug Development: XtalPi’s AI-Powered Generative siRNA Therapeutics Design PlatformBOSTON, MA, UNITED STATES, August 24, 2026 /EINPresswire.com/ -- Small interfering RNA (siRNA) therapeutics are RNA-based medicines that silence disease-associated genes by directing the sequence-specific degradation of target mRNA, thereby...
10.06.2026XtalPi Announces Strategic Partnership with a Leading Biopharma to Develop Oral Small Molecule Therapeutics for a GPCR TargetBOSTON and SHENZHEN, China, June 10, 2026 /PRNewswire/ -- XtalPi (2228.HK), a leading platform in artificial intelligence (AI) and robotics-driven drug discovery, today announced a strategic partnership with a prominent international biopha...
29.05.2026Beyond Serendipity: Redefining Rational Molecular Glue Discovery via AI-driven MethodologiesBOSTON, MA, UNITED STATES, May 29, 2026 /EINPresswire.com/ -- Beyond Serendipity: Redefining Rational Molecular Glue Discovery via AI-driven methodologies As a new generation of proximity-induced therapeutics, molecular glues represent a un...
29.05.2026Integrated Autonomous Lab Platforms Are Transforming Scientific ResearchBOSTON, MA, UNITED STATES, May 29, 2026 /EINPresswire.com/ -- How Integrated Autonomous Lab Platforms Are Transforming Scientific Research The modern research and development landscape is undergoing a significant transformation. For decades...
29.05.2026XtalPi Receives Second Payment from DoveTree; First Oncology Asset Advances into IND-Enabling StudiesBOSTON, May 29, 2026 /PRNewswire/ -- XtalPi (2228.HK), an AI- and robotics- powered drug discovery platform, announced that its strategic collaboration with innovative biopharmaceutical company DoveTree Medicines Unus Inc. has achieved subs...
29.05.2026Advanced Crystal Structure Prediction Platform: Essential Selection Guide for Material ScienceBOSTON, MA, UNITED STATES, May 29, 2026 /EINPresswire.com/ -- Advanced Crystal Structure Prediction Platform: Essential Selection Guide for Material Science Executive Summary: Selecting the right crystal form is crucial for the performance ...
29.05.2026Accelerating Drug Discovery with AI and Next-Generation AutomationBOSTON, MA, UNITED STATES, May 29, 2026 /EINPresswire.com/ -- Accelerating Drug Discovery with AI and Next-Generation Automation The pharmaceutical industry is currently witnessing a transformative shift as the traditional, trial-and-error ...
29.05.2026XtalPi: Defining the Next-Generation R&D Paradigm Through AI for ScienceBOSTON, MA, UNITED STATES, May 29, 2026 /EINPresswire.com/ -- The methods that drive scientific discovery are undergoing a quiet but substantial transformation. Empirical, iterative experimentation has driven extraordinary progress across b...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In